EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis

Tamer Hodrob iD, Ibrahim Ismail, Alaaeddin Abusalameh, Celina R Andonie iD, Omar Ayesh, Hazem Ayesh iD

European Eating Disorders Review · 2026-03 · 34 (2) · 334-346

DOI: 10.1002/erv.70035 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift European Eating Disorders Review, online erschienen am 22.09.2025. Verfasst von Tamer Hodrob und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine. Hauptthemen laut MEDLINE: Naltrexone, Lisdexamfetamine Dimesylate, Topiramate, Binge-Eating Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the efficacy and safety of lisdexamfetamine, topiramate, and naltrexone/bupropion for treating binge eating disorder (BED) using network meta‐analysis.

Method

We systematically searched PubMed, Scopus, ClinicalTrials.gov, and Cochrane Central up to February 2025 for randomized controlled trials evaluating these medications versus placebo in adults with BED. Primary outcomes were changes in binge eating frequency and body weight; secondary outcomes included serious adverse events, discontinuation rates, and common side effects. A frequentist random‐effects network meta‐analysis was performed.

Results

Twelve trials ( n = 1988) met inclusion criteria. Both lisdexamfetamine (MD −1.61, 95% CI: −2.41 to −0.81) and topiramate (MD −1.63, 95% CI: −2.53 to −0.74) significantly reduced binge eating frequency versus placebo, with comparable efficacy. Topiramate produced the greatest weight loss (MD −5.5 kg), followed by lisdexamfetamine (−4.6 kg). Naltrexone/bupropion did not significantly reduce binge frequency (MD −2.07, 95% CI: −4.45 to 0.31). Lisdexamfetamine was associated with higher risks of dry mouth and gastrointestinal events. No significant increase in serious adverse events was observed for any medication.

Conclusions

Topiramate and lisdexamfetamine are effective for reducing binge episodes and weight in BED. Naltrexone/bupropion showed modest weight effects but lacked clear efficacy for binge reduction. These findings support topiramate and lisdexamfetamine as primary pharmacologic options for BED.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneLisdexamfetamine DimesylateTopiramateBinge-Eating DisorderBupropionHumansNetwork Meta-Analysis as TopicAdult

Stichwörter der Autor:innen

binge eating disorderlisdexamfetaminenaltrexone/bupropiontopiramateweight

Substanzen

NaltrexoneLisdexamfetamine DimesylateTopiramateBupropion

Autor:innen und Institutionen

  • Faculty of Medicine, Al-Quds University, East Jerusalem, Palestine.
  • Department of Medical Laboratory Sciences, Al-Aqsa University, Gaza, Palestine.
  • Deaconess Health System, Evansville, Indiana, USA.

ORCID-Profile: Tamer Hodrob, Celina R Andonie, Hazem Ayesh

Zitieren

APA

Hodrob, T., Ismail, I., Abusalameh, A., Andonie, C. R., Ayesh, O., & Ayesh, H. (2026). Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis. European Eating Disorders Review, 34(2), 334-346. https://doi.org/10.1002/erv.70035

Vancouver

Hodrob T, Ismail I, Abusalameh A, Andonie CR, Ayesh O, Ayesh H. Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis. European Eating Disorders Review. 2026;34(2):334-346. doi:10.1002/erv.70035

BibTeX
@article{Hodrob2026,
  author = {Hodrob, Tamer and Ismail, Ibrahim and Abusalameh, Alaaeddin and Andonie, Celina R and Ayesh, Omar and Ayesh, Hazem},
  title = {Efficacy and Safety of Lisdexamfetamine Versus Topiramate Versus Naltrexone/Bupropion in Individuals With Binge Eating Disorder: A Network Meta‐Analysis},
  journal = {European Eating Disorders Review},
  year = {2026},
  volume = {34},
  number = {2},
  pages = {334--346},
  doi = {10.1002/erv.70035}
}
Kostenlos starten →